Results 101 to 110 of about 23,537 (152)

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan   +21 more
wiley   +1 more source

miRNA Sensor HuR Compartmentalizes Ago2‐Uncoupled miRNAs to Lipid Droplets to Buffer miRNA Activity in Mammalian Cells

open access: yesThe FASEB Journal, Volume 40, Issue 11, 15 June 2026.
This study revealed a dose‐dependent miRNA buffering mechanism involving extracellular export and storage of miRNA on lipid droplets. The protein HuR facilitates miRNA buffering by dissociating miRNAs from Ago2 and promoting miRNA accumulation on lipid droplets or its extracellular export, depending on cellular requirements.
Sreemoyee Chakraborty   +3 more
wiley   +1 more source

The unfolded protein response and its activation by insulin in muscle are not altered by obesity or type 2 diabetes. [PDF]

open access: yesClin Sci (Lond)
Kruse R   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy